Next 10 |
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the ...
2024-04-19 17:05:07 ET Summary Ocugen, Inc. expects preliminary safety/efficacy data from phase 1/2 study, using OCU-410 for the treatment of patients with GA, in 2024. Preliminary safety/efficacy data from phase 1/2 study, using OCU-401ST for the treatment of patients with Starga...
2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 12:45 p.m. ET. The live conference webcast wi...
2024-03-28 16:52:13 ET Gainers: Semtech Corporation ( SMTC ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Sagimet Biosciences ( SGMT ) +5% . Photronics ( PLAB ) +5% . James River Group Holdings ( JRVR ) +4% . Losers...
2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadershi...
2024-02-28 15:30:01 ET Wedbush analyst issues UNDERPERFORM recommendation for APLS on February 28, 2024 03:01PM ET. The previous analyst recommendation was Underperform. APLS was trading at $64.035 at issue of the analyst recommendation. The overall analyst consensus : B...
2024-02-28 15:30:01 ET Wells Fargo analyst issues BUY recommendation for APLS on February 28, 2024 03:01PM ET. The previous analyst recommendation was Buy. APLS was trading at $64.035 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a con...
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the ...
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 11.97% on an annualized basis producing an average annua...